Clinical Trials Directory

Trials / Completed

CompletedNCT00312455

Effects of Fatty Acid Supplementation on Substance Dependent Individuals

Cholesterol and Fatty Acids in Cocaine Addiction Relapse

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
Sponsor
National Institute on Drug Abuse (NIDA) · NIH
Sex
All
Age
25 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Many substance dependent individuals continue to abuse a variety of substances during treatment for their disorder. Often, substance dependent individuals are co-diagnosed with depression and violence problems. Supplements of n-3 polyunsaturated fatty acids (PUFAs) may play a role in treating individuals with such substance abuse problems. The purpose of this study is to evaluate the effectiveness of the n-3 PUFAs eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) in treating relapse, aggression, and depression in substance dependent individuals.

Detailed description

Past research suggests that low levels of some PUFAs play a role in the pathophysiology of depressive and aggressive disorders. In addition, there is also evidence that PUFAs play a role in treating substance dependent individuals. The purpose of this study is to determine the efficacy of EFA and DPA in treating substance dependent individuals. Participants will be randomly assigned to receive either 3 grams of n-3 PUFAs or placebo. Treatment will last 3 months, followed by an observation period of 3 months. Study visits will occur monthly and will last approximately one hour. Study visits will include blood tests and a physical exam. Throughout the study, participants will continue to receive standard substance abuse treatment and will complete urine tests at regular intervals.

Conditions

Interventions

TypeNameDescription
DRUGPro-eicosapentaenoic acid (EPA)450 mg 5x/day
DRUGPro-docosapentaenoic acid (DPA)100mg 5x/day
DRUGPlacebo5 capsules/day

Timeline

Start date
2004-07-01
Primary completion
2005-07-01
Completion
2005-07-01
First posted
2006-04-10
Last updated
2017-01-12

Source: ClinicalTrials.gov record NCT00312455. Inclusion in this directory is not an endorsement.